These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 34593670)

  • 1. Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease.
    Lee JM; Wei SC; Lee KM; Ye BD; Mao R; Kim HS; Park SJ; Park SH; Oh EH; Im JP; Jang BI; Kim DB; Takeuchi K
    Gut Liver; 2022 May; 16(3):396-403. PubMed ID: 34593670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
    Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
    Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection.
    Liu S; He Z; Wu W; Jin H; Cui Y
    Clin Rheumatol; 2023 Sep; 42(9):2369-2376. PubMed ID: 37219751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.
    Cho YT; Chen CH; Chiu HY; Tsai TF
    J Dermatol; 2012 Mar; 39(3):269-73. PubMed ID: 22077677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy.
    Fidan S; Capkın E; Arıca DA; Durak S; Okatan IE
    Int J Rheum Dis; 2021 Feb; 24(2):254-259. PubMed ID: 33244900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
    Vassilopoulos D; Apostolopoulou A; Hadziyannis E; Papatheodoridis GV; Manolakopoulos S; Koskinas J; Manesis EK; Archimandritis AI
    Ann Rheum Dis; 2010 Jul; 69(7):1352-5. PubMed ID: 20472596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.
    Megna M; Patruno C; Bongiorno MR; Gambardella A; Guarneri C; Romita P; Raimondo A; Loconsole F; Fabbrocini G
    Clin Drug Investig; 2022 Jun; 42(6):525-531. PubMed ID: 35633470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection.
    Sayar S; Kürbüz K; Kahraman R; Öztürk O; Çalışkan Z; Doğanay HL; Özdil K
    Turk J Gastroenterol; 2020 Jul; 31(7):522-528. PubMed ID: 32897226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents.
    Papa A; Felice C; Marzo M; Andrisani G; Armuzzi A; Covino M; Mocci G; Pugliese D; De Vitis I; Gasbarrini A; Rapaccini GL; Guidi L
    J Crohns Colitis; 2013 Mar; 7(2):113-9. PubMed ID: 22464811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.
    Loras C; Gisbert JP; Mínguez M; Merino O; Bujanda L; Saro C; Domenech E; Barrio J; Andreu M; Ordás I; Vida L; Bastida G; González-Huix F; Piqueras M; Ginard D; Calvet X; Gutiérrez A; Abad A; Torres M; Panés J; Chaparro M; Pascual I; Rodriguez-Carballeira M; Fernández-Bañares F; Viver JM; Esteve M; ;
    Gut; 2010 Oct; 59(10):1340-6. PubMed ID: 20577000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of hepatitis B virus infection and risk of reactivation in rheumatic population undergoing biological therapy.
    Ditto MC; Parisi S; Varisco V; Talotta R; Batticciotto A; Antivalle M; Gerardi MC; Agosti M; Borrelli R; Fusaro E; Sarzi-Puttini P
    Clin Exp Rheumatol; 2021; 39(3):546-554. PubMed ID: 32940216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
    Lee YH; Bae SC; Song GG
    Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3).
    Loras C; Gisbert JP; Saro MC; Piqueras M; Sánchez-Montes C; Barrio J; Ordás I; Montserrat A; Ferreiro R; Zabana Y; Chaparro M; Fernández-Bañares F; Esteve M;
    J Crohns Colitis; 2014 Nov; 8(11):1529-38. PubMed ID: 25052345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors for hepatitis B vaccination and abnormal liver function in Chinese patients with inflammatory bowel disease: a single center experience.
    Leung WK; Liu KSh; Seto WK; Chan KH; Tong T; Yuen MF; Lai CL; Hung IF
    J Dig Dis; 2013 Nov; 14(11):596-603. PubMed ID: 23870196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.
    Yoo JJ; Cho EJ; Cho YY; Lee M; Lee DH; Cho Y; Lee JH; Yu SJ; Yoon SS; Yoon JH; Kim YJ
    Liver Int; 2015 Dec; 35(12):2530-6. PubMed ID: 26053357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis.
    López-Serrano P; Pérez-Calle JL; Sánchez-Tembleque MD
    World J Gastroenterol; 2013 Mar; 19(9):1342-8. PubMed ID: 23538480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection.
    Morisco F; Castiglione F; Rispo A; Stroffolini T; Sansone S; Vitale R; Guarino M; Biancone L; Caruso A; D'Inca R; Marmo R; Orlando A; Riegler G; Donnarumma L; Camera S; Zorzi F; Renna S; Bove V; Tontini G; Vecchi M; Caporaso N
    J Viral Hepat; 2013 Mar; 20(3):200-8. PubMed ID: 23383659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
    Lee YH; Bae SC; Song GG
    Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists.
    Pauly MP; Tucker LY; Szpakowski JL; Ready JB; Baer D; Hwang J; Lok AS
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1964-1973.e1. PubMed ID: 29702293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.